From protocol to practice: Safety interventions based on real-world implementation of the SQuID protocol

Clicks: 6
ID: 325214
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #66 of 151 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 151 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Purpose Development and implementation of an emergency department protocol for use of subcutaneous (SQ) insulin in patients with mild to moderate diabetic ketoacidosis (DKA) is described. Summary Diabetes is on the rise worldwide in what has been described as a coming tsunami, with proportional increases in DKA, outstripping the availability of intensive care unit (ICU) and intermediate care unit beds. Historically, the complexity of care for DKA and safety concerns restricting use of intravenous insulin infusion on medical floors have required admission to an ICU. A potential solution to these concerns is in use of subcutaneous insulin for treating DKA, which avoids an insulin infusion and the intensity of monitoring that requires nursing staff ratios only available in the ICU. Recently our multidisciplinary team implemented a protocol for use of subcutaneous (SQ) insulin in patients with mild- to moderate-severity DKA presenting to the emergency department (ED) called the SQuID (Subcutaneous Insulin in Diabetic Ketoacidosis) protocol. This was followed with a second study expanding the locations to which these patients can be admitted. We are currently expanding this protocol in some of our community affiliate hospitals. Now in its fourth year, this protocol has been highly successful, with over 75% of patients with mild to moderate DKA (nearly all who are eligible) being treated on SQuID and resulting in a more than 33% reduction in ICU utilization for this population. Conclusion Implementation of the SQuiD protocol along with comprehensive education, ongoing monitoring, and targeted modifications to reduce hypoglycemia risk has advanced our institution’s efforts to provide a safe alternative to conventional DKA management.
Reference Key
openalex_W7203683418 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Julianne Yeary, Ryan Schneider, Richard T Griffey
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag235
URL
https://doi.org/10.1093/ajhp/zxag235
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.